Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000727637 | SCV000854920 | uncertain significance | not provided | 2017-10-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000727637 | SCV001066952 | benign | not provided | 2018-05-02 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004586903 | SCV005075795 | likely benign | not specified | 2024-04-03 | criteria provided, single submitter | clinical testing | Variant summary: THRB c.532+8G>C alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00028 in 251144 control chromosomes, predominantly at a frequency of 0.004 within the African or African-American subpopulation in the gnomAD database, suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. To our knowledge, no occurrence of c.532+8G>C in individuals affected with Thyroid Hormone Resistance, Generalized, Autosomal Dominant and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 592487). Based on the evidence outlined above, the variant was classified as likely benign. |